NCT04791566 is a Phase 4 clinical trial of Dexamethasone 1 mg/kg in Intestinal Obstruction and Ileus, sponsored by Mirjana Cihoric.

Who is sponsoring NCT04791566?

NCT04791566 is sponsored by Mirjana Cihoric.

What drugs are being tested in NCT04791566?

Interventions in NCT04791566: Dexamethasone 1 mg/kg, Physiologic saline.

What condition does NCT04791566 study?

NCT04791566 studies Intestinal Obstruction and Ileus, Perforated Viscus, Sepsis, Pathophysiology, Inflammatory Response.

Is NCT04791566 still recruiting?

NCT04791566 is currently completed. Last updated 14 December 2022.

Last reviewed 2022-12-14 · How we verify

NCT04791566

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Preoperative High-dose Dexamethasone and Emergency Laparotomy

Completed Phase 4 Last updated 14 December 2022

What this trial tests

Phase 4 trial testing Dexamethasone 1 mg/kg in Intestinal Obstruction and Ileus in 120 participants. Completed in 9 December 2022.

Timeline

1 March 2021

Primary endpoint
9 October 2022

9 December 2022

Quick facts

Lead sponsor	Mirjana Cihoric
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	120
Start date	1 March 2021
Primary completion	9 October 2022
Estimated completion	9 December 2022
Sites	1 location across Denmark

Drugs / interventions tested

Dexamethasone 1 mg/kg — full drug profile →
Physiologic saline — full drug profile →

Conditions studied

Intestinal Obstruction and Ileus — all drugs for Intestinal Obstruction and Ileus →
Perforated Viscus — all drugs for Perforated Viscus →
Sepsis — all drugs for Sepsis →
Pathophysiology — all drugs for Pathophysiology →

Sponsor

Mirjana Cihoric — full company profile →

Who can join

18 and older, any sex, with Intestinal Obstruction and Ileus or Perforated Viscus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this trial is to evaluate the effect of high-dose glucocorticoid on inflammatory response and recovery after emergency laparotomy in participants with intestinal obstruction and perforated viscus. Primary outcome is the reduction of C-reactive protein on postoperative day 1. Secondary outcomes are organ specific complications in the post anaesthesia phase, endothel and inflammatory markers, fluid status, preload dependency, pain, lung function, nausea and mobilization during the first 5 days after surgery, . The investigators hypothesize, that a preoperative single high dose of glucocorticoid reduces systemic inflammatory response after emergency laparotomy.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Preoperative high dose of dexamethasone in emergency laparotomy: randomized clinical trial.
Cihoric M, Kehlet H, Lauritsen ML, Højlund J, et al · · 2024 · cited 12× · PMID 39028763 · DOI 10.1093/bjs/znae130

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04791566 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mirjana Cihoric
Last refreshed: 14 December 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04791566.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing